- Home
- LYEL
as 06-20-2025 4:00pm EST
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 207.7M | IPO Year: | 2021 |
| Target Price: | $20.00 | AVG Volume (30 days): | 249.1K |
| Analyst Decision: | Sell | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -24.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.65 - $45.42 | Next Earning Date: | 08-06-2025 |
| Revenue: | $65,000 | Revenue Growth: | -4.41% |
| Revenue Growth (this year): | -60.42% | Revenue Growth (next year): | -14.11% |
Stock Insider Trading Activity of Lyell Immunopharma Inc. (LYEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BRAWLEY OTIS W | LYEL | Director | Mar 31 '25 | Buy | $0.56 | 35,640 | $19,958.40 | 35,640 |
Latest Lyell Immunopharma Inc. News
LYEL Breaking Stock News: Dive into LYEL Ticker-Specific Updates for Smart Investing
Clinical Trials Arena
3 days ago
Lyell reports new clinical data from trial of large B-cell lymphoma therapy
MT Newswires
4 days ago
Lyell Immunopharma Says LYL314 Shows 'Robust' Responses in Large B-Cell Lymphoma Trial
GlobeNewswire
4 days ago
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
GlobeNewswire
12 days ago
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
GlobeNewswire
17 days ago
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
Associated Press Finance
a month ago
Lyell Immunopharma: Q1 Earnings Snapshot
GlobeNewswire
a month ago
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2025
GlobeNewswire
2 months ago
Lyell Immunopharma Announces Oral Presentation of New Clinical Data from the Phase 1/2 Trial of LYL314 for the Treatment of Large B-cell Lymphoma at the International Conference on Malignant Lymphoma (ICML) 2025
Compare LYEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LYEL Lyell Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.